SELLAS Cancer Vaccine Phase III Trial Succeeds: AML Mortality Risk Reduced by 41%, Stock Price Soars 156.36%
IT Home, November 18 — U.S. biopharmaceutical company SELLAS Life Sciences Group announced yesterday that an experimental cancer vaccine it developed has achieved positive results in a pivotal Phase 3 clinical trial for acute myeloid leukemia (AML).
Trial data show that the vaccine reduced the risk of death by 41%, with median overall survival reaching 24 months, significantly higher than the current best available treatment.
According to an announcement released by SELLAS, the experimental cancer vaccine, named galinpepimut-S (GPS), met its primary endpoint — overall survival (OS) — in the Phase 3 REGAL clinical trial. Median overall survival was 24 months for patients receiving the vaccine, compared with 14.7 months for patients in the control group, representing a 41% reduction in the risk of death, with a hazard ratio (HR) of 0.59 and a two-sided P value of 0.035.
According to Reuters, SELLAS's stock price rose sharply after the clinical trial results were announced, with intraday gains at one point exceeding 243%. By the close of U.S. trading, the gain had narrowed to 156.36%, closing at $19.15.

The trial enrolled a total of 126 patients with acute myeloid leukemia who had achieved complete remission again after second-line or later salvage therapy but were not suitable for or unable to undergo allogeneic hematopoietic stem cell transplantation. GPS was used as monotherapy maintenance treatment in the trial, aiming to help patients prolong remission and survival.
According to a statement issued by Memorial Sloan Kettering Cancer Center (MSK) on November 17, GPS is an off-the-shelf cancer vaccine composed of synthetic peptides that can stimulate the human immune system to recognize and attack cancer cells expressing the WT1 protein. WT1 is an antigen expressed in the cancer cells of more than 95% of patients with acute myeloid leukemia.
The vaccine was developed by Dr. David A. Scheinberg and his team, immunotherapy researchers at MSK. In 2014, MSK licensed GPS to SELLAS, which continued to advance clinical development. Unlike personalized cancer vaccines that must be individually designed based on a patient's tumor characteristics, GPS is an off-the-shelf vaccine that can be used in multiple patients.
Regarding safety, SELLAS said GPS was generally well tolerated, with no new safety signals identified. Treatment-related adverse events were mainly grade 1 to 2 mild or moderate reactions, the most common of which were local injection-site reactions.
SELLAS said the company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss an accelerated filing strategy and to advance preparations for a Biologics License Application (BLA) for GPS, with the goal of submitting the application in the first half of 2027. However, the vaccine is still in the clinical development stage and has not yet received marketing approval.
IT Home previously reported that a personalized mRNA melanoma vaccine jointly developed by Moderna and Merck had also published positive clinical trial data. The achievement of the primary endpoint by GPS in a Phase 3 trial for acute myeloid leukemia provides new clinical data for cancer vaccines in the field of hematologic oncology treatment.
- "Moderna & Merck Announce World's First mRNA Cancer Vaccine Phase III Clinical Trial Proves Effective: Postoperative Recurrence Risk of Melanoma Significantly Reduced, Stock Price Soars 150%"
- "Moderna Joins Forces with Merck to Create a New Milestone: mRNA Cancer Vaccine Reduces 5-Year Recurrence Risk by 49%"